HRP20200993T1 - Uporaba inhibitora telomeraze imetelstata za liječenje mijelodisplastičnog sindroma - Google Patents
Uporaba inhibitora telomeraze imetelstata za liječenje mijelodisplastičnog sindroma Download PDFInfo
- Publication number
- HRP20200993T1 HRP20200993T1 HRP20200993TT HRP20200993T HRP20200993T1 HR P20200993 T1 HRP20200993 T1 HR P20200993T1 HR P20200993T T HRP20200993T T HR P20200993TT HR P20200993 T HRP20200993 T HR P20200993T HR P20200993 T1 HRP20200993 T1 HR P20200993T1
- Authority
- HR
- Croatia
- Prior art keywords
- telomerase inhibitor
- use according
- inhibitor
- telomerase
- effective amount
- Prior art date
Links
- 239000003277 telomerase inhibitor Substances 0.000 title claims 50
- 201000003793 Myelodysplastic syndrome Diseases 0.000 title claims 7
- LVZYXEALRXBLJZ-ISQYCPACSA-N f60ne4xb53 Chemical compound N1([C@@H]2O[C@@H]([C@H](C2)NP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)NP(S)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)N)COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)OCC(O)CNC(=O)CCCCCCCCCCCCCCC)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=NC=NC(N)=C3N=C2)C=CC(N)=NC1=O LVZYXEALRXBLJZ-ISQYCPACSA-N 0.000 title claims 2
- 229950004291 imetelstat Drugs 0.000 title claims 2
- 229940123582 Telomerase inhibitor Drugs 0.000 claims 49
- 108010019437 Janus Kinase 2 Proteins 0.000 claims 3
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 2
- 210000003593 megakaryocyte Anatomy 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 102200087780 rs77375493 Human genes 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000034656 Contusions Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010033661 Pancytopenia Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 208000009527 Refractory anemia Diseases 0.000 claims 1
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 claims 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 208000027503 bloody stool Diseases 0.000 claims 1
- 208000024389 cytopenia Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 208000001780 epistaxis Diseases 0.000 claims 1
- 208000035861 hematochezia Diseases 0.000 claims 1
- IEVORMRANFJJFR-NMZIRJKDSA-A imetelstat sodium Chemical group [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].N1([C@@H]2O[C@@H]([C@H](C2)NP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)NP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)N)COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)OCC(O)CNC(=O)CCCCCCCCCCCCCCC)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=NC=NC(N)=C3N=C2)C=CC(N)=NC1=O IEVORMRANFJJFR-NMZIRJKDSA-A 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 206010034754 petechiae Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010067959 refractory cytopenia with multilineage dysplasia Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 206010042772 syncope Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Compounds Of Unknown Constitution (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (28)
1. Inhibitor telomeraze za uporabu u ublažavanju najmanje jednog simptoma koji je rezultat mijelodisplastičnog sindroma kod pojedinca, pri čemu, inhibitor telomeraze je imetelstat ili njegova farmaceutski prihvatljiva sol.
2. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 1, naznačen time što najmanje jedan simptom sadrži kratak dah, umor, slabost, nesvjesticu, krvarenje iz nosa, pojavu modrica, krvarenje iz usta ili desni, krvavu stolicu, petehije ili moždani udar.
3. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 1, naznačen time što je mijelodisplastični sindrom izabran iz grupe koja se sastoji od refraktorne anemije, refraktorne anemije sa viškom blasta, refraktorne citopenije sa multi-linijskom displazijom, refraktorne citopenije sa jedno-linijskom displazijom i kronične mijelomonocitne leukemije (CMML).
4. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 3, naznačen time što, mijelodisplastični sindrom (MDS) je kronična mijelomonocitna leukemija (CMML).
5. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 1, naznačen time što inhibitor smanjuje proliferaciju neoplastičnih progenitorskih stanica kod pojedinca kojem je postavljena dijagnoza ili za kojeg se sumnja da ima mijelodisplastični sindrom.
6. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 5, naznačen time što smanjena proliferacija neoplastičnih progenitorskih stanica rezultira u brojevima trombocita manjim od oko 600 x 103 / µL u krvi pojedinca.
7. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 1, naznačen time što inhibitor telomeraze smanjuje fibrozu koštane srži kod pojedinca kojem je postavljena dijagnoza ili za kojeg se sumnja da ima mijelodisplastični sindrom.
8. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 1, naznačen time što pojedinac ima anemiju ili zahtjeva transfuziju krvi.
9. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time što pojedinac nosi V617F mutaciju za dobivanje funkcije u genu za Janus kinazu 2 (JAK2) i uporaba inhibitora telomeraze smanjuje postotak JAK2 V617F alelskog opterećenja kod pojedinca.
10. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što je pojedinac rezistentan ili intolerantan na prethodnu terapiju koja nije bazirana na inhibitoru telomeraze.
11. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što inhibitor telomeraze se koristi sa farmaceutski prihvatljivim ekscipijentom.
12. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što inhibitor telomeraze je formuliran za oralnu, intravensku, subkutanu, intramuskularnu, topikalnu, intraperitonealnu, intranazalnu, inhalacijsku ili intraokularnu primjenu.
13. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što su jedna ili više neoplastičnih progenitorskih stanica dovedene u kontakt sa inhibitorom telomeraze.
14. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što efikasna količina inhibitora telomeraze je 3.5 mg/kg do 11.7 mg/kg.
15. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što efikasna količina inhibitora telomeraze je 5 mg/kg do 11.7 mg/kg.
16. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što efikasna količina inhibitora telomeraze je 6.5 mg/kg do 11.7 mg/kg.
17. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što efikasna količina inhibitora telomeraze je 7.5 mg/kg do 9.4 mg/kg.
18. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što efikasna količina inhibitora telomeraze je 9.5 mg/kg do 11.7 mg/kg.
19. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što inhibitor telomeraze ne inhibira rast megakariocite ovisan od citokina.
20. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što inhibitor telomeraze inhibira rast megakariocite neovisan od citokina.
21. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što inhibitor telomeraze inhibira CFU-mega.
22. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 21, naznačen time što inhibicija CFU-Mega je neovisna od smanjenja u alelskom opterećenju JAK2.
23. Inhibitor telomeraze za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što inhibitor telomeraze je imetelstat natrij.
24. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 23, naznačen time što učinkovita količina inhibitora telomeraze je 3.5 mg/kg do 11.7 mg/kg.
25. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 23, naznačen time što učinkovita količina inhibitora telomeraze je 5 mg/kg do 11.7 mg/kg.
26. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 23, naznačen time što učinkovita količina inhibitora telomeraze je 6.5 mg/kg do 11.7 mg/kg.
27. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 23, naznačen time što učinkovita količina inhibitora telomeraze je 7.5 mg/kg do 9.4 mg/kg.
28. Inhibitor telomeraze za uporabu prema patentnom zahtjevu 23, naznačen time što učinkovita količina inhibitora telomeraze je 9.5 mg/kg do 11.7 mg/kg.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734941P | 2012-12-07 | 2012-12-07 | |
| US201361799069P | 2013-03-15 | 2013-03-15 | |
| US13/841,711 US9375485B2 (en) | 2012-12-07 | 2013-03-15 | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| US201361900347P | 2013-11-05 | 2013-11-05 | |
| EP18196690.4A EP3456333B8 (en) | 2012-12-07 | 2013-11-15 | Use of the telomerase inhibitor imetelstat for the treatment of myelodysplastic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200993T1 true HRP20200993T1 (hr) | 2020-11-27 |
Family
ID=50883867
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191784TT HRP20191784T1 (hr) | 2012-12-07 | 2013-11-15 | Uporaba inhibitora telomeraze imetelstata za liječenje mijelofibroze |
| HRP20240624TT HRP20240624T1 (hr) | 2012-12-07 | 2013-11-15 | Inhibitor telomeraze imetelstat za liječenje mijeloproliferativnih poremećaja i mijeloproliferativne neoplazme |
| HRP20200993TT HRP20200993T1 (hr) | 2012-12-07 | 2020-06-24 | Uporaba inhibitora telomeraze imetelstata za liječenje mijelodisplastičnog sindroma |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191784TT HRP20191784T1 (hr) | 2012-12-07 | 2013-11-15 | Uporaba inhibitora telomeraze imetelstata za liječenje mijelofibroze |
| HRP20240624TT HRP20240624T1 (hr) | 2012-12-07 | 2013-11-15 | Inhibitor telomeraze imetelstat za liječenje mijeloproliferativnih poremećaja i mijeloproliferativne neoplazme |
Country Status (36)
| Country | Link |
|---|---|
| EP (3) | EP2928477B1 (hr) |
| JP (5) | JP6433911B2 (hr) |
| KR (3) | KR102294819B1 (hr) |
| CN (2) | CN104936602B (hr) |
| AP (1) | AP2015008504A0 (hr) |
| AU (4) | AU2013356533B2 (hr) |
| BR (1) | BR112015013260A2 (hr) |
| CA (2) | CA3188494A1 (hr) |
| CL (2) | CL2015001530A1 (hr) |
| CY (2) | CY1122169T1 (hr) |
| DK (3) | DK3646876T3 (hr) |
| EA (1) | EA032973B1 (hr) |
| ES (3) | ES2982897T3 (hr) |
| FI (2) | FI3646876T3 (hr) |
| FR (1) | FR25C1016I1 (hr) |
| HK (1) | HK1210940A1 (hr) |
| HR (3) | HRP20191784T1 (hr) |
| HU (4) | HUE045098T2 (hr) |
| IL (3) | IL317233A (hr) |
| LT (3) | LT3456333T (hr) |
| MA (2) | MA38193B1 (hr) |
| ME (1) | ME03538B (hr) |
| MX (3) | MX372753B (hr) |
| MY (1) | MY180634A (hr) |
| NZ (1) | NZ708920A (hr) |
| PH (2) | PH12019501008A1 (hr) |
| PL (3) | PL3456333T3 (hr) |
| PT (3) | PT3646876T (hr) |
| RS (2) | RS59363B1 (hr) |
| SG (3) | SG10201802926XA (hr) |
| SI (3) | SI2928477T1 (hr) |
| SM (2) | SMT201900567T1 (hr) |
| TN (1) | TN2015000249A1 (hr) |
| UA (3) | UA117116C2 (hr) |
| WO (1) | WO2014088785A1 (hr) |
| ZA (3) | ZA201504124B (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1778711T3 (en) | 2004-07-02 | 2017-10-02 | Geron Corp | SYNTHESIS OF PROTECTED 3'-AMINONUCLEOSIDE MONOMERS |
| SG10201912203XA (en) | 2013-08-07 | 2020-02-27 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| EP3539547A1 (en) * | 2013-11-06 | 2019-09-18 | Mayo Foundation for Medical Education and Research | Methods and materials for treating hematological malignancies |
| AU2016250576C1 (en) | 2015-04-23 | 2021-05-06 | Geron Corporation | Methods of polynucleotide preparation using multivalent cation salt compositions |
| EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| EP3658156A1 (en) * | 2017-07-28 | 2020-06-03 | Geron Corporation | Methods of treating myelodysplastic syndrome |
| IL308399B1 (en) | 2018-04-30 | 2025-04-01 | Kartos Therapeutics Inc | Methods of treating cancer |
| JP2021525795A (ja) * | 2018-05-25 | 2021-09-27 | カルトス セラピューティクス，インコーポレイテッド | 骨髄増殖性腫瘍を治療する方法 |
| MA53348A (fr) * | 2018-07-31 | 2022-05-04 | Geron Corp | Méthodes d'identification de patients susceptibles de bénéficier d'un traitement à l'aide d'un inhibiteur de télomérase |
| JP7650798B2 (ja) | 2018-11-29 | 2025-03-25 | ジェロン・コーポレーション | 骨髄異形成症候群を治療する方法 |
| MX2022005354A (es) * | 2019-11-04 | 2022-10-21 | Geron Corp | Uso de un inhibidor de la cinasa janus y un inhibidor de la telomerasa para el tratamiento de neoplasias mieloproliferativas. |
| JP2021157248A (ja) * | 2020-03-25 | 2021-10-07 | パイオニア株式会社 | 状況出力装置 |
| US20240108734A1 (en) * | 2021-01-22 | 2024-04-04 | The Regents Of The University Of California | Methods for treating and ameliorating cancer |
| WO2024259369A1 (en) * | 2023-06-14 | 2024-12-19 | Rarecells Inc. | Compositions targeting giant cells in blood disorders |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
| US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
| US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
| US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
| US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| JP2001507229A (ja) | 1996-12-20 | 2001-06-05 | ジェロン コーポレイション | テロメラーゼのｒｎａ成分を検出および阻害するための方法 |
| US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
| AU2004209428A1 (en) * | 2003-01-31 | 2004-08-19 | Jessie L.-S. Au | Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors |
| CN1244592C (zh) * | 2003-07-11 | 2006-03-08 | 暨南大学 | 抑制白血病细胞端粒酶活性的反义核酸及其应用 |
| SI1667522T1 (en) | 2003-09-09 | 2018-04-30 | Geron Corporation | Modified oligonucleotides for the inhibition of telomerase |
| US20050282893A1 (en) * | 2004-01-30 | 2005-12-22 | Au Jessie L | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors |
| DK1778711T3 (en) | 2004-07-02 | 2017-10-02 | Geron Corp | SYNTHESIS OF PROTECTED 3'-AMINONUCLEOSIDE MONOMERS |
| FR2877013A1 (fr) | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| US20060166221A1 (en) | 2005-01-21 | 2006-07-27 | Bahou Wadie F | Methods of diagnosing essential thrombocythemia |
| WO2006113426A2 (en) * | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of telomerase and tubulin activities |
| US7998938B2 (en) | 2005-04-15 | 2011-08-16 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| US20070224598A1 (en) | 2006-03-15 | 2007-09-27 | The Methodist Hospital Research Institute | System and method for detection of mutations in JAK2 polynucleotides |
| US20080021013A1 (en) | 2006-07-21 | 2008-01-24 | Cephalon, Inc. | JAK inhibitors for treatment of myeloproliferative disorders |
| ES2986404T3 (es) | 2006-10-30 | 2024-11-11 | Geron Corp | Inhibidor de telomerasa y gemcitabina combinados para el tratamiento del cáncer |
| CN101220044B (zh) * | 2008-01-21 | 2010-06-02 | 中国药科大学 | 端粒酶抑制剂及其制备方法和用途 |
-
2013
- 2013-11-15 JP JP2015546492A patent/JP6433911B2/ja active Active
- 2013-11-15 ES ES19187756T patent/ES2982897T3/es active Active
- 2013-11-15 SI SI201331556T patent/SI2928477T1/sl unknown
- 2013-11-15 CN CN201380069553.6A patent/CN104936602B/zh active Active
- 2013-11-15 KR KR1020157017240A patent/KR102294819B1/ko active Active
- 2013-11-15 EP EP13861008.4A patent/EP2928477B1/en active Active
- 2013-11-15 HU HUE13861008A patent/HUE045098T2/hu unknown
- 2013-11-15 KR KR1020237005641A patent/KR20230028590A/ko not_active Ceased
- 2013-11-15 RS RSP20191271 patent/RS59363B1/sr unknown
- 2013-11-15 CA CA3188494A patent/CA3188494A1/en active Pending
- 2013-11-15 NZ NZ708920A patent/NZ708920A/en unknown
- 2013-11-15 RS RS20200723A patent/RS60401B1/sr unknown
- 2013-11-15 CN CN202010575187.3A patent/CN111617252A/zh active Pending
- 2013-11-15 UA UAA201505480A patent/UA117116C2/uk unknown
- 2013-11-15 SG SG10201802926XA patent/SG10201802926XA/en unknown
- 2013-11-15 FI FIEP19187756.2T patent/FI3646876T3/fi active
- 2013-11-15 HR HRP20191784TT patent/HRP20191784T1/hr unknown
- 2013-11-15 HK HK15111700.1A patent/HK1210940A1/xx unknown
- 2013-11-15 PT PT191877562T patent/PT3646876T/pt unknown
- 2013-11-15 AP AP2015008504A patent/AP2015008504A0/xx unknown
- 2013-11-15 PL PL18196690T patent/PL3456333T3/pl unknown
- 2013-11-15 CA CA2892907A patent/CA2892907C/en active Active
- 2013-11-15 BR BR112015013260-0A patent/BR112015013260A2/pt not_active Application Discontinuation
- 2013-11-15 ES ES18196690T patent/ES2789176T3/es active Active
- 2013-11-15 KR KR1020217026717A patent/KR102662590B1/ko active Active
- 2013-11-15 SM SM20190567T patent/SMT201900567T1/it unknown
- 2013-11-15 MA MA38193A patent/MA38193B1/fr unknown
- 2013-11-15 SM SM20200328T patent/SMT202000328T1/it unknown
- 2013-11-15 DK DK19187756.2T patent/DK3646876T3/da active
- 2013-11-15 LT LTEP18196690.4T patent/LT3456333T/lt unknown
- 2013-11-15 EP EP18196690.4A patent/EP3456333B8/en active Active
- 2013-11-15 MX MX2015007169A patent/MX372753B/es active IP Right Grant
- 2013-11-15 MA MA45504A patent/MA45504B1/fr unknown
- 2013-11-15 LT LTEP19187756.2T patent/LT3646876T/lt unknown
- 2013-11-15 PT PT138610084T patent/PT2928477T/pt unknown
- 2013-11-15 WO PCT/US2013/070437 patent/WO2014088785A1/en not_active Application Discontinuation
- 2013-11-15 EP EP19187756.2A patent/EP3646876B1/en active Active
- 2013-11-15 HU HUE18196690A patent/HUE049858T2/hu unknown
- 2013-11-15 HU HUE19187756A patent/HUE066402T2/hu unknown
- 2013-11-15 AU AU2013356533A patent/AU2013356533B2/en active Active
- 2013-11-15 UA UAA202100419A patent/UA128370C2/uk unknown
- 2013-11-15 IL IL317233A patent/IL317233A/en unknown
- 2013-11-15 HR HRP20240624TT patent/HRP20240624T1/hr unknown
- 2013-11-15 LT LTEP13861008.4T patent/LT2928477T/lt unknown
- 2013-11-15 PH PH1/2019/501008A patent/PH12019501008A1/en unknown
- 2013-11-15 DK DK18196690.4T patent/DK3456333T3/da active
- 2013-11-15 PL PL13861008T patent/PL2928477T3/pl unknown
- 2013-11-15 SG SG11201504383TA patent/SG11201504383TA/en unknown
- 2013-11-15 MY MYPI2015001459A patent/MY180634A/en unknown
- 2013-11-15 IL IL280144A patent/IL280144B2/en unknown
- 2013-11-15 DK DK13861008.4T patent/DK2928477T3/da active
- 2013-11-15 SI SI201331716T patent/SI3456333T1/sl unknown
- 2013-11-15 ME MEP-2019-273A patent/ME03538B/me unknown
- 2013-11-15 EA EA201590878A patent/EA032973B1/ru unknown
- 2013-11-15 SI SI201332080T patent/SI3646876T1/sl unknown
- 2013-11-15 SG SG10202103341SA patent/SG10202103341SA/en unknown
- 2013-11-15 ES ES13861008T patent/ES2744790T3/es active Active
- 2013-11-15 PT PT181966904T patent/PT3456333T/pt unknown
- 2013-11-15 PL PL19187756.2T patent/PL3646876T3/pl unknown
- 2013-11-15 UA UAA201800703A patent/UA126015C2/uk unknown
-
2015
- 2015-06-04 CL CL2015001530A patent/CL2015001530A1/es unknown
- 2015-06-05 PH PH12015501282A patent/PH12015501282A1/en unknown
- 2015-06-05 MX MX2022015437A patent/MX2022015437A/es unknown
- 2015-06-05 MX MX2020003276A patent/MX2020003276A/es unknown
- 2015-06-05 TN TNP2015000249A patent/TN2015000249A1/fr unknown
- 2015-06-07 IL IL23926615A patent/IL239266B/en active IP Right Grant
- 2015-06-08 ZA ZA2015/04124A patent/ZA201504124B/en unknown
-
2017
- 2017-08-24 CL CL2017002156A patent/CL2017002156A1/es unknown
- 2017-12-04 JP JP2017232485A patent/JP6998191B2/ja active Active
-
2018
- 2018-12-20 AU AU2018282364A patent/AU2018282364A1/en not_active Abandoned
-
2019
- 2019-10-14 CY CY20191101076T patent/CY1122169T1/el unknown
- 2019-12-23 JP JP2019231517A patent/JP2020041001A/ja active Pending
-
2020
- 2020-06-23 CY CY20201100568T patent/CY1123206T1/el unknown
- 2020-06-24 HR HRP20200993TT patent/HRP20200993T1/hr unknown
- 2020-11-09 AU AU2020267142A patent/AU2020267142C1/en active Active
-
2021
- 2021-11-12 ZA ZA2021/08991A patent/ZA202108991B/en unknown
-
2022
- 2022-01-06 JP JP2022000951A patent/JP7288098B2/ja active Active
- 2022-10-12 JP JP2022163881A patent/JP2022179684A/ja active Pending
- 2022-11-11 ZA ZA2022/12327A patent/ZA202212327B/en unknown
-
2024
- 2024-05-13 AU AU2024203138A patent/AU2024203138A1/en active Pending
-
2025
- 2025-05-07 FR FR25C1016C patent/FR25C1016I1/fr active Active
- 2025-05-07 FI FIC20250019C patent/FIC20250019I1/fi unknown
- 2025-05-07 HU HUS2500019C patent/HUS2500019I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200993T1 (hr) | Uporaba inhibitora telomeraze imetelstata za liječenje mijelodisplastičnog sindroma | |
| JP2016512230A5 (hr) | ||
| HRP20120419T1 (hr) | Fluoro deoksitetrahidrouridini kao inhibitori citidin deaminaze | |
| PH12014501279A1 (en) | Smoking article with improved airflow | |
| SA517382236B1 (ar) | نيوكليدات بيورين مستبدلة بـ 2- n6 معدل مستبدل بــــ بيتا-d-2´-ديوكسي-2´-ألفا-فلورو-2 ´-بيتا-c لمعالجة hcv | |
| JP2016504307A5 (hr) | ||
| JP2020535122A5 (hr) | ||
| HRP20191477T1 (hr) | Farmaceutski sastav s-ketamin hidroklorida | |
| NZ709365A (en) | Smoking article comprising an airflow directing element | |
| BR112015020047A2 (pt) | artigo fumígeno com um elemento de direcionamento do fluxo de ar compreendendo um agente de modificação de aerossol | |
| WO2014190163A3 (en) | Combination therapy for mds | |
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| RU2017134519A (ru) | Терапевтические композиции и способы применения для лечения рака | |
| JP2014500312A5 (hr) | ||
| MX2023002994A (es) | Formas de dosificacion oral y de liberacion controlada gastrorresistentes. | |
| JP2015511625A5 (hr) | ||
| PH12015501113A1 (en) | Combination therapy with volasertib | |
| MX2020010738A (es) | Formulaciones de ciclosporina para uso en el tratamiento del sindrome de bronquiolitis obliterante (bos). | |
| HRP20191322T1 (hr) | Antitumorska kombinacija koja sadži kabazitaksel i cisplatin | |
| BR112014007773A2 (pt) | artigo de fumagem de múltiplos segmentos | |
| Starczynowski et al. | Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q | |
| Ye et al. | Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged≥ 60 years and has lower toxicities: Comparison with low-dose chemotherapy | |
| CA3037779A1 (en) | Treatment of inflammatory bowel disease with nucleoside triphosphate disphoshohydrolase, p2y2 antagonist and/or p2y6 antagonist | |
| Zhou et al. | A110 THORACIC CANCERS: PATHOGENESIS AND NOVEL TARGETS: Downregulation Of Partitioning Defective 3 Is Responsible For Lung Cancer Progression And Chemoresistance | |
| Schepke et al. | 128 Endoscopic banding ligation versus propranolol for the primary prevention of variceal bleeding in cirrhosis: a randomized controlled multicenter trial |